This is a list of adverse effects of the anti-cancer drug pazopanib, sorted by frequency of occurrence.

Very common Very common (>10% incidence) adverse effects include:

Reduced appetite Headache Taste changes High blood pressureUsually occurs within the first 18 weeks of treatment. 39% of cases develop within the first 9 days of treatment. Diarrhoea Abdominal pain Nausea Vomiting Hair colour change Hand-foot syndrome Hair loss Rash Fatigue Increased alanine aminotransferase Increased aspartate aminotransferase Tumour pain‡ Myelosuppression‡This includes leucopenia, thrombocytopenia and neutropenia. Stomatitis‡ Exfoliative rash‡ Skin hyperpigmentation‡ Weight loss‡

Common Common (1–10% incidence) adverse effects include:

Tumour pain† Myelosuppression†This includes leucopenia, lymphopenia, thrombocytopenia and neutropenia. Underactive thyroid Dehydration Low level of phosphate in the blood Dizziness Lethargy Paraesthesia Peripheral sensory neuropathy Blurred vision Hot flush Venous thromboembolic event Flushing Nose bleed Voice anomalies Shortness of breath Coughing up blood Stomatitis Indigestion Flatulence Abdominal distension Dry mouth Mouth ulceration Hyperbilirubinaemia Abnormal liver function Hepatotoxicity Skin hypopigmentation Dry skin Itchiness Erythema Skin depigmentation Hyperhidrosis Joint pain Muscle aches Muscle spasms Protein in the urine Mucosal inflammation Weakness Oedema Chest pain Weight loss† Increased blood creatinine Lipase increased Decreased white blood cell count Blood TSH decreased Amylase increased Gamma-glutamyltransferase increased Increased blood pressure Increased blood urea Abnormal liver function test Gingival infection‡ Dizziness Insomnia Peripheral sensory neuropathy Heart dysfunction Blurred vision Low heart rate Left ventricular dysfunction Bleeding (including haemorrhage) High blood sugar Low blood sugar

Uncommon Uncommon (0.1–1% incidence) adverse effects include:

Torsades de pointes Heart failure Liver failure GI perforation (may be fatal) Fistula formation

Rare Rare (<0.1% incidence) adverse effects include: Reversible posterior leukoencephalopathy syndrome

Notes † Denotes side effects seen at the above frequency only in clinical trials performed in people with renal cell carcinoma.

‡ Denotes side effects seen at the above frequency only in clinical trials done in people with soft tissue sarcomas.

References